TITLE

Eribulin approved for advanced breast cancer

AUTHOR(S)
Traynor, Kate
PUB. DATE
January 2011
SOURCE
American Journal of Health-System Pharmacy;1/1/2011, Vol. 68 Issue 1, p6
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that Eisai Inc. and the U.S. Food & Drug Administration (FDA) have announced that eribulin mesylate injection can be used for the treatment of metastatic breast cancer. This would be applicable to patients who have previously undergone treatment with an anthracycline and a taxane. FDA reportedly approved the drug on the basis of a clinical trial that showed a 2.5-month increase in survival time among patients treated with eribulin as compared to other treatments.
ACCESSION #
56944996

 

Related Articles

  • Ipilimumab approved for metastatic melanoma. Traynor, Kate // American Journal of Health-System Pharmacy;5/1/2011, Vol. 68 Issue 9, p768 

    The article reports that the Food and Drug Administration (FDA) approved ipilimumab, to be marketed as 'Yervoy' by Bristol-Myers Squibb, for the treatment of metastatic melanoma. It offers information on the product, an immunoglobulin G1&subk; (IgG1&subk;) monoclonal antibody, which binds to the...

  • FDA approves prostate cancer treatment that inhibits testosterone synthesis. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;6/1/2011, Vol. 68 Issue 11, p960 

    No abstract available.

  • Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date. Lemech, Charlotte; Infante, Jeffrey; Arkenau, Hendrik-Tobias // Drugs;2013, Vol. 73 Issue 8, p767 

    Previously characterized by a median overall survival of between 6 and 12 months, metastatic melanoma now has a number of novel and effective treatment options. The ability to target the mitogen-activated protein kinase (MAPK) pathway with BRAF (v-raf murine sarcoma viral oncogene homolog B1) or...

  • Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC). COHEN, MARTIN H.; CORTAZAR, PATRICIA; JUSTICE, ROBERT; PAZDUR, RICHARD // Oncologist;Dec2010, Vol. 15 Issue 12, p1352 

    On July 2, 2009, the U.S. Food and Drug Administration approved pemetrexed injection (Alimta® Injection; Eli Lilly and Company, Indianapolis, IN) for maintenance treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed...

  • Regorafenib Tablets (Stivarga®). Elliott, William T.; Chan, James // Internal Medicine Alert;4/15/2013, Vol. 35 Issue 7, p53 

    The article reports on the approval by the Food and Drug Administration of an oral multikinase inhibitor regorafenib which is marketed by Bayer HealthCare Pharmaceuticals as Stivarga, for the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumors.

  • Erratum to: Dinutuximab: First Global Approval. Dhillon, Sohita // Drugs;Oct2015, Vol. 75 Issue 15, p1831 

    A correction to the article "Dinutuximab: First Global Approval" that was published in the October 13, 2015 issue is presented.

  • Taxanes for the Treatment of Metastatic Breast Cancer. Gradishar, W. J. // Breast Cancer: Basic & Clinical Research;2012, Issue 6, p159 

    Taxanes have remained a cornerstone of breast cancer treatment over the past three decades, improving the lives of patients with both early- and late-stage disease. The purpose of this review is to summarize the current role of taxanes, including an albumin-bound formulation that enhances...

  • Ado-trastuzumab emtansine approved for advanced breast cancer. Traynor, Kate // American Journal of Health-System Pharmacy;4/1/2013, Vol. 70 Issue 7, p562 

    The article reports that the Food and Drug Administration has approved Genentech's adotrastuzumab emtansine, an antibody-drug conjugate, for the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. It mentions that the drug will be available under the...

  • Monoclonal Antibodies for Multiple Myeloma. Helwick, Caroline // Oncology Pharmacist;May2014, Vol. 7 Issue 2, p3 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics